Zura Bio Ltd. Files 8-K/A Amendment on Officer/Director Changes
Ticker: ZURA · Form: 8-K/A · Filed: Jul 2, 2024 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K/A |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50, $440,000, $585,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Zura Bio Ltd. amended its 8-K filing regarding director and officer changes.
AI Summary
Zura Bio Ltd. filed an 8-K/A amendment on July 2, 2024, related to events reported as of March 24, 2024. The filing concerns the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. It also notes Zura Bio Ltd. was formerly known as JATT Acquisition Corp, with a name change effective April 7, 2021.
Why It Matters
This amendment clarifies changes in Zura Bio Ltd.'s leadership and compensation structures, which can impact company governance and investor confidence.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and primarily concerns corporate governance and personnel changes, not immediate financial distress or significant operational shifts.
Key Players & Entities
- Zura Bio Ltd (company) — Registrant
- JATT Acquisition Corp (company) — Former company name
- April 7, 2021 (date) — Date of name change
- March 24, 2024 (date) — Earliest event reported date
- July 2, 2024 (date) — Filing date
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A filing amends items related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was Zura Bio Ltd.'s former name?
Zura Bio Ltd.'s former name was JATT Acquisition Corp.
When did the name change from JATT Acquisition Corp to Zura Bio Ltd. occur?
The name change occurred on April 7, 2021.
What is the earliest event date reported in this filing?
The earliest event reported date is March 24, 2024.
What is the filing date of this 8-K/A amendment?
This 8-K/A amendment was filed on July 2, 2024.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-07-02 16:01:30
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
- $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma
- $440,000 — n Mr. Lisicki's annual base salary from $440,000 to $585,000 and an increase in his targ
- $585,000 — i's annual base salary from $440,000 to $585,000 and an increase in his target bonus opp
Filing Documents
- tm2418704d1_8ka.htm (8-K/A) — 29KB
- 0001104659-24-077323.txt ( ) — 244KB
- zura-20240324.xsd (EX-101.SCH) — 3KB
- zura-20240324_def.xml (EX-101.DEF) — 26KB
- zura-20240324_lab.xml (EX-101.LAB) — 36KB
- zura-20240324_pre.xml (EX-101.PRE) — 25KB
- tm2418704d1_8ka_htm.xml (XML) — 5KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. As previously disclosed on March 24, 2024, the board of directors (the " Board ") of Zura Bio Limited (" Zura ", the " Company ") approved a Chief Executive Officer (" CEO ") transition from Someit Sidhu to Robert Lisicki, effective April 8, 2024. On July 1, 2024, the Board approved an increase in Mr. Lisicki's annual base salary from $440,000 to $585,000 and an increase in his target bonus opportunity from 40% of his annual base salary to 50% of his annual base salary, with retroactive effect as of April 8, 2024, in light of such promotion.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 2, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer